Form 4: Ionis Pharma EVP Sells Shares Under 10b5-1 Plan

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, executed pre-planned stock option exercises and subsequent sales of common stock.

Summary

• Patrick R. O'Neil, Executive Vice President, Chief Legal Officer, and General Counsel of Ionis Pharmaceuticals, Inc. (IONS), reported changes in his beneficial ownership of common stock.
• On September 2, 2025, O'Neil exercised options to acquire 13,050 shares of common stock at an exercise price of $32.60 per share.
• Immediately following the exercise on September 2, 2025, he sold 13,050 shares of common stock at a weighted average price of $54.5148, with prices ranging from $54.50 to $54.59.
• On September 3, 2025, O'Neil exercised options to acquire 14,000 shares of common stock at an exercise price of $37.58 per share.
• Also on September 3, 2025, he sold 65,475 shares of common stock at a weighted average price of $60.89, with prices ranging from $60.3418 to $61.34.
• Additionally on September 3, 2025, he exercised options to acquire 13,050 shares of common stock at an exercise price of $32.60 per share.
• Following this exercise, he sold 11,375 shares of common stock at a weighted average price of $61.42, with prices ranging from $61.35 to $61.48.
• Further on September 3, 2025, O'Neil exercised options to acquire 49,800 shares of common stock at an exercise price of $53.77 per share.
• All sales were conducted pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025.
• Following these transactions, O'Neil's direct beneficial ownership of common stock was 57,130 shares after the first set of transactions on September 2, 2025, then 5,655 shares after the second set of transactions on September 3, 2025, then 7,330 shares after the third set of transactions on September 3, 2025, and finally 57,130 shares after the last exercise on September 3, 2025.

Sentiment

Score: 6

Explanation: The filing reports routine, pre-planned insider transactions (option exercises and sales) under a 10b5-1 plan, which is a neutral event. The executive is realizing value from previously granted options, which is a positive for the individual but generally neutral for the company's immediate outlook.

Positives

• The executive is realizing value from previously granted stock options, indicating successful vesting and potentially favorable stock performance since the grant dates.
• All reported sales were conducted under a pre-established Rule 10b5-1 Trading Plan, which demonstrates a commitment to compliance and reduces concerns about opportunistic insider selling.

Negatives

• The transactions result in a reduction of direct beneficial ownership of common stock by a key executive, which could be interpreted as a slight decrease in insider alignment, although mitigated by the 10b5-1 plan.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction; it solely reports past insider transactions.

Management Comments

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request to Ionis Pharmaceuticals, Inc., any security holder, or the SEC staff.

Industry Context

Insider transactions, particularly those involving option exercises and subsequent sales, are common occurrences for executives in publicly traded companies across all industries. The use of a Rule 10b5-1 trading plan is a standard practice for executives to manage their equity compensation in a compliant and pre-planned manner, mitigating concerns about trading on material non-public information.

Comparison to Industry Standards

• The execution of stock option exercises and sales under a Rule 10b5-1 plan is a widely accepted and standard practice for corporate executives to manage their personal finances and diversify their holdings while adhering to insider trading regulations. This aligns with best practices observed among executives at comparable biotechnology and pharmaceutical companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The sales represent a reduction in direct insider ownership, but the pre-planned nature under a 10b5-1 plan mitigates concerns about negative sentiment. It also indicates the executive is realizing value from their compensation.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing details routine, pre-planned insider transactions (option exercises and sales) by a key executive. These transactions are executed under a Rule 10b5-1 plan, which indicates they are not based on new, material non-public information. While the executive is reducing direct beneficial ownership, this is a common practice for executives to diversify holdings and realize value from compensation. The event itself does not provide new information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Options, Executive Compensation, Share Sale, 10b5-1 Plan, Patrick O'Neil